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cardiomyopathy (PPCM) and to record rates of implantable cardioverter-deﬁbrillator (ICD) use.Background PPCM is a rare, life-threatening disease. The use of ICDs has not been clearly understood in this patient group.
Identiﬁcation of the predictors of persistent LV dysfunction can help select patients at risk for sudden cardiac death.Methods A retrospective study was conducted at 2 academic centers between January 1, 1999, and December 31, 2012.
Clinical and demographic variables and delivery records of patients with a diagnosis of PPCM (International
Classiﬁcation of Diseases, 9th Revision code 674.5) were reviewed. Improvement in LV function was noted from
echocardiography reports.Results The total sample comprised 100 patients, of whom 55% were African Americans, 39% were Caucasians, and
6% were Hispanic, with a mean age of 30  6 years. Mean left ventricular ejection fraction (LVEF) at diagnosis was
28  9%. Forty-two percent of patients showed improvement in LVEF over a mean duration of 33  21 months.
Postpartum diagnosis (hazard ratio: 3.0; p ¼ 0.01) and Caucasian/Hispanic race (hazard ratio: 2.2; p ¼ 0.01) were
predictors of improvement in LVEF. Only 7 of the 58 patients (12%) who did not have improvement in their LVEF had
an ICD implanted. There were 11 deaths, with a trend toward higher mortality in those who did not display improved
LV function (15% vs. 5%; p ¼ 0.1).Conclusions More than one-third of women with PPCM improve LV function with delayed recovery noted in the majority of these
patients. Caucasians and those diagnosed in the postpartum period appear to be the most likely to recover. The rate
of ICD implantation for primary prevention of sudden cardiac death in this patient group is low. (J Am Coll Cardiol
2014;63:2831–9) ª 2014 by the American College of Cardiology FoundationPeripartum cardiomyopathy (PPCM) is a rare, idiopathic
cardiomyopathy characterized by the development of systolic
heart failure toward the end of pregnancy or in the months
after delivery (1,2). The reported incidence shows signiﬁ-
cant geodemographic variation, from 1 in 500 live births
in Haiti to 1 in 4000 live births in the United States (3–6).
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and African-American race (1,2,7–9).
Despite the recognition of this disease as a separate entity in
1937, the mortality rates are not yet well characterized (8–19),
ranging from 4% to 50% (2,8–19). At least one-fourth of
deaths in PPCM are sudden cardiac deaths presumed to be
caused by ventricular tachyarrhythmias (16). Sudden cardiac
death in these young women could potentially be averted by
insertion of an implantable cardioverter-deﬁbrillator (ICD),
and cardiac resynchronization therapy devices (CRTDs) may
reduce progression to end-stage myocardial dysfunction. The
American College of Cardiology Foundation/American
Heart Association 2009 guidelines recommend implantation
of an ICD for primary prevention of sudden cardiac death in
all patients with ischemic and nonischemic cardiomyopathy
with ejection fraction (EF) 35% in patients with New York
Heart Association (NYHA) functional class II and III and
EF <30% in patients with NYHA class I if there is no
improvement in EF after 3 to 6 months of guideline-directed
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2832optimal medical therapy (20). To
date, no studies have reported
the use of ICDs for primary pre-
vention in this patient group.
PPCM is also presumed to be
associated with a higher likeli-
hood of recovery of left ventricular
(LV) function than cardiomyop-
athy attributable to other causes
(2,10,17,19,21). Thus, prediction
of who will recover from the dis-
ease helps determine who mightbest beneﬁt from an ICD. Previous studies have shown that
baseline LV EF >30%, LV end-diastolic diameter <5.5 cm,
older age, and Caucasian race predicted recovery of LV func-
tion (22–29). However, either these were single-center studies
with small sample sizes of 55 patients, or the information
was obtained from other countries and surveys that were sub-
ject to ascertainment, recall, and selection bias or were not
controlled for other covariates.
We thus wanted to study the mortality and LV recovery
rates and examine ICD implantation rates at tertiary aca-
demic centers that offer a good mix of patients of different
ethnicities. We sought to identify the predictors for LV
recovery and the current rates of ICD use.Figure 1 Flow Chart of Patient Cohort
Seven patients were excluded, which yielded a total of 100 patients in the ﬁnal
cohort.Methods
This was a retrospective study conducted at 2 large tertiary
care academic centers, the University of Kansas (Kansas
City, Kansas) and the Detroit Medical Center (Detroit,
Michigan), where cardiovascular and high-risk pregnancy
services are available. Approval was obtained from the
institutional review boards at both institutions.
Patients
All patients >18 years of age who were diagnosed with
postpartum/peripartum cardiomyopathy at the 2 centers
were studied. The medical records of these patients were
identiﬁed by use of International Classiﬁcation of Diseases-
9th Revision diagnostic codes for PPCM (674.50, 674.51,
674.52, 674.53, and 674.54) that were used for discharge
diagnoses from the hospital or ambulatory clinic visits. At
the University of Kansas, medical records were obtained for
patients diagnosed between January 1, 2004, and August 31,
2010. At the Detroit Medical Center, records were obtained
for patients who were diagnosed with PPCM between
January 1, 1999, and December 31, 2010. All delivery re-
cords and follow-up encounters were reviewed for clinical
and demographic information. Patients with a history of
prior cardiomyopathy attributable to other causes or struc-
tural heart disease were excluded. Each patient was followed
up until December 2012 for any improvement in EF. Time
to recovery was noted for patients who had improvement in
LV function. For those without any improvement in EF,the date of the last echocardiogram was used to measure the
period during which no improvement in EF was observed.
ICD implantation was also noted. All-cause mortality was
obtained from the Social Security Death Index and
conﬁrmed by chart review when available. For mortality
analysis, time to death was used for those who died, and
December 2012 was used as the last follow-up date for all
those who survived.
Assessment of EF. EFs at the time of diagnosis of PPCM
were recorded and considered baseline EFs. Each patient
was followed up over time to assess EF, and the EF from the
last echocardiogram report was noted for those without LV
improvement. For patients who had an improvement in EF,
the EF and the time to improvement in EF were noted.
Deﬁnition of improvement. An EF >50% at follow-up
was considered complete recovery. If the EF remained
<35%, it was considered no improvement. If the follow-up
EF was between 35% and 50%, the improvement was
considered partial provided that there was a >10% absolute
increase from baseline (e.g., from 35% to >45%). If patients
had either partial or complete improvement, they were
included in the “any improvement” category used for the
analysis.
Statistical Analysis
Statistical analysis of the data was performed with SAS
version 9.3 (SAS Inc., Cary, North Carolina). The chi-
square test was used for comparisons of categorical data
and Student t test for continuous parameters. A Cox pro-
portional hazards model was used to assess the predictors of
any improvement in EF after adjustment for signiﬁcant
covariates. Univariate predictors were initially obtained, and
Figure 2
Time to Diagnosis of Peripartum Cardiomyopathy
From Delivery
The majority of patients were diagnosed at 1 week postpartum.
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2833if p < 0.1, they were included in the multivariate analysis.
Baseline EF was tested both as a continuous variable and as
a categorical variable (EF <30% and >30%) to determine
whether it predicted recovery or mortality. Statistical sig-
niﬁcance was considered present when p < 0.05 in the
multivariate analysis. Kaplan-Meier curves for improvement
in EF and mortality were constructed for the entire
population.Table 1 Baseline Characteristics of All Patients
Total (N ¼ 100) Imp
Age, yrs 30  6.5
African-American race, % 55
Baseline EF, % 28  9.9
Diabetes mellitus, % 29
Hypertension, % 33
Gestational hypertension, % 33
Preeclampsia, % 36
Hyperlipidemia, % 9
Multiparity, % 61
Tobacco abuse, % 30
Alcohol, % 11
Cesarean section, % 56
Family history of cardiomyopathy, % 13
Left atrium enlarged, % 64
Postpartum diagnosis, % 71
QRS duration, ms 85  18
Creatinine, mg/dl 0.8  0.7
Hemoglobin, mg/dl 10.7  1.7
Beta-blocker, % 82
ACEI/ARB, % 85
Values are mean  SD or %.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receResults
The ﬂow chart of cohort assembly is illustrated in Figure 1.
The ﬁnal cohort consisted of 100 patients with a mean age
of 30  6.5 years. Mean duration of follow-up for recovery
of LV function was 35  21 months. African Americans
predominated in the sample (55%), with 39% Caucasians
and 6% Hispanics.
Maternal and fetal characteristics. Preeclampsia was
diagnosed in 36% of the women in the study; 61% were
multiparous. The majority of patients were diagnosed after
delivery (71%). The mean time to diagnosis of PPCM was
1.3  4 weeks from delivery. Figure 2 shows the time to
diagnosis for each patient. Forty patients had preterm de-
livery before 37 weeks, and tocolytic agents were used in 9.
The cesarean section rate was 56%. Three women had
stillbirths. The mean birth weight of the neonates was 3 
0.92 kg. Thirty-ﬁve women had subsequent pregnancies.
Median NYHA class was III. Thirty percent of patients
were in NYHA class I, 17% were in class II, 45% were in
class III, and 8% were in class IV. There were 4 patients
with QRS duration >120 ms at baseline. Among patients
who did not recover LV function, 1 woman had a ventricular
assist device implanted. Two women were listed for heart
transplantation.
LV recovery. Forty-two of 100 patients (42%) had “any
improvement” in EF over a mean duration of 33  21
months. Of these patients, 23 had complete improvement,
whereas 19 had partial recovery of LV function. Baselinerovement (n ¼ 42) No Improvement (n ¼ 58) p Value
30  7 30  6.2 0.7
48 65 0.09
29  9 28  10 0.9
23 32 0.3
35 31 0.8
33 32 0.9
40 32 0.4
7 10 0.6
52 67 0.12
39 24 0.12
14 8 0.3
59 54 0.46
14 12 0.7
64 63 0.9
83 62 0.02
83  21 86  16 0.4
0.82  0.2 0.9  0.9 0.6
10.7  1.5 10.8  1.8 0.6
89 78 0.2
83 86 0.7
ptor blocker; EF ¼ ejection fraction.
Table 2 Distribution of Baseline EF Against Follow-Up EF
Baseline EF
Follow-Up EF
Improved (per Study Deﬁnition)<20% 20%–30% 31%–50% >50%
<20% 8 2 2 1 3/13 (23)
20%–30% 10 7 12 13 22/42 (52)
31%–50% 7 13 16 9 17/45 (38)
Values are n or n (%).
EF ¼ ejection fraction.
Pillarisetti et al. JACC Vol. 63, No. 25, 2014
Peripartum Cardiomyopathy Course and ICD Use July 1, 2014:2831–9
2834characteristics of patients with and without improvement in
EF are shown in Table 1. The distribution of baseline EF
versus follow-up EF is shown in Table 2. The mean baseline
EF was 28  9.9%. The mean EF at follow-up for the entire
group was 34  18% during a mean follow-up of 35  21
months. Figure 3 demonstrates the range of improvement in
EF that occurred with different baseline EFs of <20%, 20%
to 30%, and >30%.
In women who had any improvement (partial or com-
plete) in LV function, the mean baseline EF was 29  8%,
and the mean follow-up EF was 52  5%. The mean
baseline EF in patients with complete recovery was 30 
9%, and the mean follow-up EF was 56% over a mean of
26  22 months. Among these women, only 4 had complete
improvement within 6 months. Delayed complete recovery
beyond 6 months was noted in 83% (19 of 23 patients). The
mean baseline EF in patients with partial improvement was
30  9%, and the mean follow-up EF was 48%, which was
achieved after a mean of 40  17 months. Univariate and
multivariate analysis of predictors of LV recovery (any
improvement) revealed that race (Caucasian and Hispanic)
and postpartum diagnosis were predictors of LV recovery,
whereas there was a trend for no improvement in LV
function in patients with diabetes mellitus (see Table 3 for
multivariate predictors). A Kaplan-Meier curve for recovery
of LV function is shown in Figure 4.Figure 3
Follow-Up Ejection Fraction Versus
Baseline Ejection Fraction
Median ejection fraction (EF) with range (vertical bar) and ﬁrst and third quartiles
(box) noted at follow-up in patients with baseline EF >20%, 20% to 30%, and 31%
to 50% at diagnosis.Mortality. The majority of the women were treated
with optimal therapy for heart failure (beta-blockers and
angiotensin-converting enzyme inhibitors/angiotensin re-
ceptor blockers). There was no difference in the use of
beta-blockers and angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers among patients with or without
recovery of LV function (Table 1). Eleven women died
during an mean follow-up of 98  33 months. Nine were in
the group that did not experience recovery of LV function.
The mean time from last follow-up echocardiogram to death
was 13  12 months. In the 2 patients who improved but
died, mean time to improvement was 23 months. Mortality
occurred at a mean of 83  1.4 months in these 2 patients.
There was a trend toward higher mortality in the group that
did not recover LV function (15% vs. 5%; p ¼ 0.09). Only 1
had an ICD but died of intractable heart failure. Two other
women died of arrhythmic causes, whereas the cause of death
was unknown in the other 8 patients. A Kaplan-Meier sur-
vival curve for both groups is shown in Figure 5. The 5 pa-
tients with no follow-up data who were excluded from the
study are noted to be alive.
ICD use. Thirteen women had ICDs implanted at some
point, including 2 with CRTDs. Six women among the
42 who had complete recovery from PPCM (14%)
received an ICD early in their follow-up, whereas 7 devices
were present in the group without any EF improvement
(n ¼ 7 of 58; 12%). Fifty-four of the 58 patients who did
not recover had an EF 35%, of whom 53 (1 patient
was in NYHA class IV) qualiﬁed for an ICD device for
primary prevention of sudden cardiac death; only 7 (13%)
had a device implanted. An ICD was implanted for pri-
mary prevention in 12 patients and for secondary pre-
vention in 1 patient.
Outcome in subsequent pregnancy. Four of the 35
women who had subsequent pregnancies died (11%). MeanTable 3 Multivariate Predictors of LV Recovery
Predictors Hazard Ratio
95% Conﬁdence
Interval p Value
Race (African American vs. other) 0.45 0.2–0.8 0.01
Postpartum diagnosis 3.0 1.2–7.0 0.01
Diabetes mellitus 0.4 0.2–1.0 0.06
LV ¼ left ventricular.
Figure 4 Improvement in Ejection Fraction
Kaplan-Meier curve showing proportion of patients whose ejection fraction improved over time.
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2835baseline EF in these patients was 28  10%, and follow-
up EF was 30  18% after a mean follow-up period of
36  17 months. There was a high rate of fetal loss (36%;
n ¼ 12 of 35).Figure 5 Kaplan-Meier Survival Curve for Those Who Improved (Grou
Kaplan-Meier estimates were used to calculate the mortality rates in patients with and wAfrican-American versus Caucasian/Hispanic women.
Table 4 shows the distribution of baseline characteristics in
African-American and Caucasian/Hispanic women. There
was no difference in the time to diagnosis in either groupp A) and Those Without Improvement (Group B)
ithout improvement in ejection fraction.
Table 4 Differences in Baseline Characteristics on the Basis of Race
Caucasian þ Hispanic
(n ¼ 39 þ 6)
African American
(n ¼ 55) p Value
Age, yrs 30  7 30.4  6 0.76
Diabetes mellitus, % 20 36 0.07
Hypertension, % 37 29 0.35
Gestational hypertension, % 46 21 0.008
Preeclampsia, % 53 21 0.001
Hyperlipidemia, % 11 7 0.5
Multiparity, % 48 70 0.024
Tobacco abuse, % 24 34 0.27
Alcohol, % 8 12 0.002
Cesarean section, % 70 45 0.09
Family history of cardiomyopathy, % 11 14 0.6
Left atrium enlarged, % 58 49 0.84
Postpartum diagnosis, % 80 63 0.07
QRS duration, ms 81  17 87.6  18.0 0.13
Creatinine, mg/dl 0.8  0.1 0.9  1.0 0.4
Hemoglobin, mg/dl 10.6  1.7 10.8  1.7 0.5
Beta-blocker, % 95 65 0.002
ACEI/ARB, % 92 74 0.13
Baseline EF, % 27.6  9.0 30.0  9.8 0.2
Values are mean  SD or %.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin receptor blocker.
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2836(1.7  5 weeks vs. 0.96  4 weeks; p ¼ 0.4). Mean EF at
follow-up was 36.3  18% in Caucasian/Hispanic women
and 32  17.7% in African-American women (p ¼ 0.2).
Fifty-one percent of Caucasian/Hispanic women improved
compared with 34% of African-American women (p ¼ 0.09)
during a mean of 24  20 months versus 44  16 months
(p ¼ 0.001). Caucasians appeared to have a lower mortality,
but the difference was not statistically signiﬁcant (4% [2 of
45] vs. 16% [9 of 55]; p ¼ 0.10). There was no difference in
the time to death (13  35 months vs. 32  32 months;
p ¼ 0.42) or the use of ICDs between both groups (11% vs.
14%; p ¼ 0.6).
Discussion
The major ﬁndings of our study are as follows. 1) A sub-
stantial proportion of patients with PPCM recover LV
function (42%); complete recovery occurred in 23% of pa-
tients in the present study. 2) Our follow-up duration was
long enough to note delayed complete recovery of EF
beyond 6 months in the majority of the Caucasian and
African-American patients (83%). 3) The present study
underlines the high mortality rate (11%) in these young
women. 4) This is one of the ﬁrst studies to address the use
of ICDs and suggests their underimplantation according to
guidelines.
PPCM is distinct from other types of cardiomyopathy,
although the symptoms resemble those of dilated cardio-
myopathies. Oxidative stress, genetic susceptibility, auto-
immunity, and myocarditis have all been implicated in the
pathogenesis (1,2). Complete recovery of ventricularfunction may occur in a substantial proportion of women,
which is unusual in other forms of cardiomyopathy (6).
Complete recovery was seen in 23% of patients in the pre-
sent study, with partial recovery in 19%. Other studies have
reported complete recovery rates between 20% and 60%
(21–29). Factors predictive of recovery suggested in prior
studies included baseline ejection fraction 30% and LV
end-diastolic diameter <5.5 cm (22,24–26). All of these
studies were from single centers and involved fewer than 55
patients with limited follow-up, and none of the studies were
controlled for other covariates. The present study is one of
the largest studies in the United States with clinical and
echocardiographic variables that were included in the model,
unlike the study by Goland et al. (29), which primarily
assessed echocardiographic predictors. A recent prospective
study by McNamara et al. (30) that followed 100 patients in
the United States showed complete recovery in 65% of
women at 6 months and demonstrated that baseline EF and
race were predictors of recovery and outcomes. That study,
however, was limited by 6 months of follow-up. In the
present study, Caucasians had a better recovery rate and
earlier recovery than African-American women (24 months
vs. 44 months), but baseline EF was not a predictor. A
recent report of 176 South African patients with PPCM
followed up for only 6 months concluded that older age and
lower LV end-systolic diameter, but not EF, predicted re-
covery (27); however, this may not be applicable to our
patient group given the racial and genetic differences. We did
not ﬁnd age to be a predictor but did conﬁrm that race and
postpartum diagnosis were predictors. The differences may
also be explained by our longer follow-up duration, because
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2837delayed recovery of EF beyond 6 months has been reported
in 3 other recent studies (18,31,32). Biteker et al. (31) noted
that only 14% of Turkish women had EF recovery in the
ﬁrst 6 months, whereas another 33% of women recovered
beyond 6 months. Modi et al. (18) reported a median time
to recovery of 54 months in African-American women in
the United States, whereas Fett et al. (32) followed 32
PPCM patients in Haiti and found that the mean duration
to LV recovery was 35 months. This is important to note
because some have concluded that EF recovery occurs in the
ﬁrst 6 months and that persistence of LV dysfunction
beyond 6 months is a marker of worse survival (2). In the
present study, complete recovery of EF within 6 months was
seen in only 4 patients (17%), whereas delayed recovery
occurred in 83% of patients. To the best of our knowledge,
the present study is the ﬁrst to note delayed recovery of EF
in Caucasian women with PPCM. The Kaplan-Meier curve
in Figure 4 shows a 10% nonrecovery rate after 5 years.
Long-term follow-up of these patients is thus needed, and
serial clinical and echocardiographic assessments of LV
function recovery should be made.
Predictors of LV recovery in our study were race and
postpartum diagnosis, as was suggested previously in other
studies (23,33). There are several possible reasons why an
antepartum diagnosis could represent a worse outcome.
Early presentation could represent more severe disease.
Treatment with optimal heart failure medications is limited
during pregnancy at a stage when therapy is needed the
most. It is also possible that these women had subclinical
PPCM with a prior pregnancy that remained undiagnosed
and had progressed to become clinically manifest in the
antepartum stage of the subsequent pregnancy. There was a
trend for worse outcomes in patients with diabetes mellitus.
This association was not reported previously with PPCM
but is true in the case of structural heart disease. Prior studies
were small, and few included clinical variables. With the
rising incidence of diabetes mellitus in the young patient
group, this association may have now become evident.
There was no difference in maternal mortality in our study
in women who had a subsequent pregnancy (4 of 35 vs. 7 of
65); however, fetal mortality was high at 36%, which is
similar to the 40% rate described by Modi et al. (18). This is
in contrast to no perinatal mortality reported by Elkayam
et al. (15). Similarly, the high cesarean section rate of 56%
noted in our study was also reported in other studies
(15,25,34). A cesarean section rate of 32% was reported by
Elkayam et al. (25), for which obstetric pathogenesis was
stated to be a reason in 70%, there was a cardiac cause in
10%, and the cause was unknown in 20%.
Therapy for heart failure consists of optimal medical
management and an ICD/CRTD for primary prevention
of sudden cardiac death (20). More than 80% of the patients
in our study were taking beta-blockers and angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers.
Small studies that predated guideline-driven heart failure
therapy have reported higher mortality rates (9). Recentstudies in the current era, including the present study, show
better outcomes (22,34). Some new therapies currently
under investigation are pentoxifylline and bromocriptine
(34–36). A very recent prospective study evaluated treat-
ment with bromocriptine and suggests potential beneﬁt in
the European population (34). Cardiac resynchronization
therapy has also been shown to be effective in this patient
group (37).
Device therapy for primary prevention of sudden cardiac
death in patients with PPCM was not speciﬁcally addressed
in the 2008 device therapy guidelines (38). The present
study suggests that implantation of devices in this patient
group is low. Another study reported that 7 of 182 patients
with PPCM had ventricular arrhythmias and underwent
ICD implantation in a tertiary hospital in California; 3 of
the ICDs were CRTDs (39). Similarly, 3 of 14 patients
without improvement underwent ICD implantation in a
recent prospective study in Europe during a follow-up of
6  3 months (34). The reasons for the low implantation
rates of ICDs in our study are not very clear, but possible
reasons include lack of speciﬁc guidelines on the use of ICDs
in PPCM patients, socioeconomic factors, patient compli-
ance, access to long-term follow-up care, and possible
follow-up by physicians other than cardiologists who are
probably not very familiar with the device indications for
primary prevention of sudden cardiac death.
The need and the optimal time for device implantation in
women with PPCM is difﬁcult to state, because even though
delayed EF recovery may occur, the risk of sudden death
before recovery remains a concern. Even though the cause of
death was primarily undetermined in the present study, it
seems only logical that most of these young people could
have died at home of sudden cardiac arrest, because death
due to decompensated heart failure would have occurred in
the hospital. Baseline EF was not shown to be a predictor of
recovery of LV function in the present study or a few others
(4,23,27). Although EF was a predictor of improvement in a
study by Goland et al. (29), they concluded that baseline EF
would not be useful as a marker for early implantation of
ICDs because it had limited sensitivity in predicting a lack of
EF improvement. The largest epidemiological study to date
of 680 PPCM patients in North Carolina reported a high
mortality rate of 16% in these young women (40). We thus
opine that patients with PPCM should undergo ICD im-
plantation if no improvement is detected within the ﬁrst 3 to
6 months. On the other hand, we could argue that prema-
ture implantation of ICDs in this patient group, in which
the majority of patients recover, could be harmful. Subcu-
taneous ICDs may thus have a role in this patient group,
with the advantage of not having an endovascular system
and the subsequent issues related to device extraction,
especially in those with clinical improvement in patients who
had a continued indication for primary prevention cease to
exist (41,42). Alternatively, life vests can also be used as a
bridge to recovery or as a bridge to ICD if the nursing
mother may ﬁnd it convenient (43).
Pillarisetti et al. JACC Vol. 63, No. 25, 2014
Peripartum Cardiomyopathy Course and ICD Use July 1, 2014:2831–9
2838Study limitations. This was a retrospective study with a
reasonable size. The exact cause of death was not available
for all patients; thus, the survival beneﬁt of ICDs could not
be demonstrated in our study. Furthermore, even though the
majority of patients were taking guideline-directed medica-
tions for heart failure, we do not know whether they were
taking optimal doses. Given the retrospective nature of the
study, we do not have information regarding why asymp-
tomatic patients in NYHA class I underwent an echocar-
diographic assessment that led to the diagnosis.
Conclusions
In the present study, 42% of the women with PPCM had
improvement in their LV function, with delayed recovery
(>6 months) noted in the majority. Caucasians/Hispanics
and those diagnosed during the postpartum period appeared
to have the highest recovery rates. Our study suggests that
ICD implantation rates for primary prevention of sudden
cardiac death in this patient group are low, and future studies
should address the utility of ICD and cardiac resynchroni-
zation therapy in these women.
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